Molecular imaging of deoxycytidine kinase activity using deoxycytidine-enhanced CEST MRI

Zheng Han, Yuguo Li, Jia Zhang, Jing Liu, Chuheng Chen, Peter C Van Zijl, Guanshu Liu

Research output: Contribution to journalArticle

Abstract

Deoxycytidine kinase (DCK) is a key enzyme for the activation of a broad spectrum of nucleoside-based chemotherapy drugs (e.g., gemcitabine); low DCK activity is one of the most important causes of cancer drug-resistance. Noninvasive imaging methods that can quantify DCK activity are invaluable for assessing tumor resistance and predicting treatment efficacy. Here we developed a "natural" MRI approach to detect DCK activity using its natural substrate deoxycytidine (dC) as the imaging probe, which can be detected directly by chemical exchange saturation transfer (CEST) MRI without any synthetic labeling. CEST MRI contrast of dC and its phosphorylated form, dCTP, successfully discriminated DCK activity in two mouse leukemia cell lines with different DCK expression. This dC-enhanced CEST MRI in xenograft leukemic cancer mouse models demonstrated that DCK( + ) tumors have a distinctive dynamic CEST contrast enhancement and a significantly higher CEST contrast than DCK( - ) tumors (AUC 0-60 min = 0.47 ± 0.25 and 0.20 ± 0.13, respectively; P = 0.026, paired Student t test, n = 4) at 1 hour after the injection of dC. dC-enhanced CEST contrast also correlated well with tumor responses to gemcitabine treatment. This study demonstrates a novel MR molecular imaging approach for predicting cancer resistance using natural, nonradioactive, nonmetallic, and clinically available agents. This method has great potential for pursuing personalized chemotherapy by stratifying patients with different DCK activity. Significance: A new molecular MRI method that detects deoxycytidine kinase activity using its natural substrate deoxycytidine has great translational potential for clinical assessment of tumor resistance and prediction of treatment efficacy.

Original languageEnglish (US)
Pages (from-to)2775-2783
Number of pages9
JournalCancer Research
Volume79
Issue number10
DOIs
StatePublished - Jan 1 2019

Fingerprint

Deoxycytidine Kinase
Deoxycytidine
Molecular Imaging
gemcitabine
Neoplasms
Drug Therapy
Enzyme Activation
Nucleosides
Drug Resistance
Heterografts
Innate Immunity
Area Under Curve
Leukemia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Molecular imaging of deoxycytidine kinase activity using deoxycytidine-enhanced CEST MRI. / Han, Zheng; Li, Yuguo; Zhang, Jia; Liu, Jing; Chen, Chuheng; Van Zijl, Peter C; Liu, Guanshu.

In: Cancer Research, Vol. 79, No. 10, 01.01.2019, p. 2775-2783.

Research output: Contribution to journalArticle

@article{e1d3551b1ac54e5c9111ec2b96e6dd21,
title = "Molecular imaging of deoxycytidine kinase activity using deoxycytidine-enhanced CEST MRI",
abstract = "Deoxycytidine kinase (DCK) is a key enzyme for the activation of a broad spectrum of nucleoside-based chemotherapy drugs (e.g., gemcitabine); low DCK activity is one of the most important causes of cancer drug-resistance. Noninvasive imaging methods that can quantify DCK activity are invaluable for assessing tumor resistance and predicting treatment efficacy. Here we developed a {"}natural{"} MRI approach to detect DCK activity using its natural substrate deoxycytidine (dC) as the imaging probe, which can be detected directly by chemical exchange saturation transfer (CEST) MRI without any synthetic labeling. CEST MRI contrast of dC and its phosphorylated form, dCTP, successfully discriminated DCK activity in two mouse leukemia cell lines with different DCK expression. This dC-enhanced CEST MRI in xenograft leukemic cancer mouse models demonstrated that DCK( + ) tumors have a distinctive dynamic CEST contrast enhancement and a significantly higher CEST contrast than DCK( - ) tumors (AUC 0-60 min = 0.47 ± 0.25 and 0.20 ± 0.13, respectively; P = 0.026, paired Student t test, n = 4) at 1 hour after the injection of dC. dC-enhanced CEST contrast also correlated well with tumor responses to gemcitabine treatment. This study demonstrates a novel MR molecular imaging approach for predicting cancer resistance using natural, nonradioactive, nonmetallic, and clinically available agents. This method has great potential for pursuing personalized chemotherapy by stratifying patients with different DCK activity. Significance: A new molecular MRI method that detects deoxycytidine kinase activity using its natural substrate deoxycytidine has great translational potential for clinical assessment of tumor resistance and prediction of treatment efficacy.",
author = "Zheng Han and Yuguo Li and Jia Zhang and Jing Liu and Chuheng Chen and {Van Zijl}, {Peter C} and Guanshu Liu",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-18-3565",
language = "English (US)",
volume = "79",
pages = "2775--2783",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Molecular imaging of deoxycytidine kinase activity using deoxycytidine-enhanced CEST MRI

AU - Han, Zheng

AU - Li, Yuguo

AU - Zhang, Jia

AU - Liu, Jing

AU - Chen, Chuheng

AU - Van Zijl, Peter C

AU - Liu, Guanshu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Deoxycytidine kinase (DCK) is a key enzyme for the activation of a broad spectrum of nucleoside-based chemotherapy drugs (e.g., gemcitabine); low DCK activity is one of the most important causes of cancer drug-resistance. Noninvasive imaging methods that can quantify DCK activity are invaluable for assessing tumor resistance and predicting treatment efficacy. Here we developed a "natural" MRI approach to detect DCK activity using its natural substrate deoxycytidine (dC) as the imaging probe, which can be detected directly by chemical exchange saturation transfer (CEST) MRI without any synthetic labeling. CEST MRI contrast of dC and its phosphorylated form, dCTP, successfully discriminated DCK activity in two mouse leukemia cell lines with different DCK expression. This dC-enhanced CEST MRI in xenograft leukemic cancer mouse models demonstrated that DCK( + ) tumors have a distinctive dynamic CEST contrast enhancement and a significantly higher CEST contrast than DCK( - ) tumors (AUC 0-60 min = 0.47 ± 0.25 and 0.20 ± 0.13, respectively; P = 0.026, paired Student t test, n = 4) at 1 hour after the injection of dC. dC-enhanced CEST contrast also correlated well with tumor responses to gemcitabine treatment. This study demonstrates a novel MR molecular imaging approach for predicting cancer resistance using natural, nonradioactive, nonmetallic, and clinically available agents. This method has great potential for pursuing personalized chemotherapy by stratifying patients with different DCK activity. Significance: A new molecular MRI method that detects deoxycytidine kinase activity using its natural substrate deoxycytidine has great translational potential for clinical assessment of tumor resistance and prediction of treatment efficacy.

AB - Deoxycytidine kinase (DCK) is a key enzyme for the activation of a broad spectrum of nucleoside-based chemotherapy drugs (e.g., gemcitabine); low DCK activity is one of the most important causes of cancer drug-resistance. Noninvasive imaging methods that can quantify DCK activity are invaluable for assessing tumor resistance and predicting treatment efficacy. Here we developed a "natural" MRI approach to detect DCK activity using its natural substrate deoxycytidine (dC) as the imaging probe, which can be detected directly by chemical exchange saturation transfer (CEST) MRI without any synthetic labeling. CEST MRI contrast of dC and its phosphorylated form, dCTP, successfully discriminated DCK activity in two mouse leukemia cell lines with different DCK expression. This dC-enhanced CEST MRI in xenograft leukemic cancer mouse models demonstrated that DCK( + ) tumors have a distinctive dynamic CEST contrast enhancement and a significantly higher CEST contrast than DCK( - ) tumors (AUC 0-60 min = 0.47 ± 0.25 and 0.20 ± 0.13, respectively; P = 0.026, paired Student t test, n = 4) at 1 hour after the injection of dC. dC-enhanced CEST contrast also correlated well with tumor responses to gemcitabine treatment. This study demonstrates a novel MR molecular imaging approach for predicting cancer resistance using natural, nonradioactive, nonmetallic, and clinically available agents. This method has great potential for pursuing personalized chemotherapy by stratifying patients with different DCK activity. Significance: A new molecular MRI method that detects deoxycytidine kinase activity using its natural substrate deoxycytidine has great translational potential for clinical assessment of tumor resistance and prediction of treatment efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85066024239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066024239&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-3565

DO - 10.1158/0008-5472.CAN-18-3565

M3 - Article

C2 - 30940660

AN - SCOPUS:85066024239

VL - 79

SP - 2775

EP - 2783

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -